The Publisher's Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 2 and 17 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fragile X Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fragile X Syndrome (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fragile X Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Fragile X Syndrome - Overview
Fragile X Syndrome - Therapeutics Development
Fragile X Syndrome - Therapeutics Assessment
Fragile X Syndrome - Companies Involved in Therapeutics Development
Fragile X Syndrome - Drug Profiles
Fragile X Syndrome - Dormant Projects
Fragile X Syndrome - Discontinued Products
Fragile X Syndrome - Product Development Milestones
- Advanced Medical Projects
- Anavex Life Sciences Corp
- Autifony Therapeutics Ltd
- Confluence Pharmaceuticals LLC
- DRI Biosciences Corp
- Epigen Biosciences Inc
- GlaxoSmithKline Plc
- GW Pharmaceuticals Plc
- Healx Ltd
- Lysogene SAS
- Marinus Pharmaceuticals Inc
- Neuren Pharmaceuticals Ltd
- Neuron Biopharma SA
- Neurotrope Bioscience Inc
- Novartis AG
- Ovid Therapeutics Inc
- Prous Institute for Biomedical Research SA
- Sage Therapeutics Inc
- Sentinel Oncology Ltd
- Seropeutics LLC
- Takeda Pharmaceutical Co Ltd
- Tetra Therapeutics
- Zynerba Pharmaceuticals Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/p4q3xz